Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: A review of prevalence, diagnosis and clinical significance

World Journal of Hepatology

Volumn 7, Issue 2, 2015, Pages 253-260

  Maldonado Rodriguez, Angelica ^a   Cevallos, Ana Maria ^b   Rojas Montes, Othon ^a   Enriquez Navarro, Karina ^a   Alvarez Muñoz, Ma Teresa ^a   Lira, Rosalia ^a  

^a HOSPITAL DE PEDIATRÍA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Clinical significance; Diagnosis; Hepatitis B virus; Human immunodeficiency virus; Occult hepatitis B; Prevalence

Indexed keywords

EID: 84922417472     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i2.253     Document Type: Short Survey

References (63)

1. Eswarappa SM, Estrela S, Brown SP. Within-host dynamics of multi-species infections: facilitation, competition and virulence. PLoS One 2012; 7: e38730 [PMID: 22737220 DOI: 10.1371/journal.pone.0038730]
2. Gürtler LG. Effect of antiretroviral HIV therapy on hepatitis B virus replication and pathogenicity. Intervirology 2014; 57: 212-217 [PMID: 25034490 DOI: 10.1159/000360942]
3. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601 [PMID: 15802978 DOI: 10.1097/01.aids.0000163936.99401.fe]
4. Hoffmann CJ, Seaberg EC, Young S, Witt MD, D'Acunto K, Phair J, Thio CL. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009; 23: 1881-1889 [PMID: 19550291 DOI: 10.1097/QAD.0b013e32832e463a]
5. Mallet V, Vallet-Pichard A, Pol S. The impact of human immunodeficiency virus on viral hepatitis. Liver Int 2011; 31 Suppl 1: 135-139 [PMID: 21205151 DOI: 10.1111/j.1478-3231.2010.02394.x]
6. Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol 2013; 35: 39-52 [PMID: 22829332 DOI: 10.1007/s00281-012-0327-7]
7. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-657 [PMID: 18715666 DOI: 10.1016/j.jhep.2008.07.014]
8. Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat 2010; 17: 1-15 [PMID: 20002296 DOI: 10.1111/j.1365-2893.2009.01245.x]
9. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-486 [PMID: 12150847 DOI: 10.1016/S1473-3099(02)00345-6]
10. Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 2014; 6: 384-393 [PMID: 25018849 DOI: 10.4254/wjh.v6.i6.384]
11. Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 2007; 45: 277-285 [PMID: 17256766 DOI: 10.1002/hep.21529]
12. Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J 2013; 10: 239 [PMID: 23870415 DOI: 10.1186/1743-422X-10-239]
13. Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, Nacca C, Sagnelli C, De Stefano G, Ferraro T, De Stefano C, Sagnelli E. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006; 20: 1253-1260 [PMID: 16816553 DOI: 10.1097/01.aids.0000232232.4 1877.2a]
14. Jain MK, Parekh NK, Hester J, Lee WM. Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. AIDS Patient Care STDS 2006; 20: 817-822 [PMID: 17192146 DOI: 10.1089/apc.2006.20.817]
15. Hollinger FB. Hepatitis B virus genetic diversity and its impact on diagnostic assays. J Viral Hepat 2007; 14 Suppl 1: 11-15 [PMID:17958637 DOI: 10.1111/j.1365-2893.2007.00910.x]
16. Ramezani A, Banifazl M, Mohraz M, Rasoolinejad M, Aghakhani A. Occult hepatitis B virus infection: A major concern in HIVinfected patients: Occult HBV in HIV. Hepat Mon 2011; 11: 7-10 [PMID: 22087108]
17. Alvarez-Muñoz MT, Maldonado-Rodriguez A, Rojas-Montes O, Torres-Ibarra R, Gutierrez-Escolano F, Vazquez-Rosales G, Gomez A, Muñoz O, Torres J, Lira R. Occult hepatitis B virus infection among Mexican human immunodeficiency virus-1-infected patients. World J Gastroenterol 2014; 20: 13530-13537 [PMID: 25309083 DOI: 10.3748/wjg.v20.i37.13530]
18. Araujo NM, Branco-Vieira M, Silva AC, Pilotto JH, Grinsztejn B, de Almeida AJ, Trepo C, Gomes SA. Occult hepatitis B virus infection in HIV-infected patients: Evaluation of biochemical, virological and molecular parameters. Hepatol Res 2008; 38: 1194-1203 [PMID:18624719 DOI: 10.1111/j.1872-034X.2008.00392.x]
19. Jardim RN, Gonçales NS, Pereira JS, Fais VC, Gonçales Junior FL. Occult hepatitis B virus infection in immunocompromised patients. Braz J Infect Dis 2008; 12: 300-305 [PMID: 19030729 DOI: 10.1590/S1413-86702008000400008]
20. Santos EA, Yoshida CF, Rolla VC, Mendes JM, Vieira IF, Arabe J, Gomes SA. Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 2003; 22: 92-98 [PMID: 12627282]
21. Sucupira MV, Mello FC, Santos EA, Niel C, Rolla VC, Arabe J, Gomes SA. Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations. Mem Inst Oswaldo Cruz 2006; 101: 655-660 [PMID:17072479 DOI: 10.1590/S0074-02762006000600013]
22. Torres-Baranda R, Bastidas-Ramírez BE, Maldonado-González M, Sánchez-Orozco LV, Vázquez-Vals E, Rodríguez-Noriega E, Panduro A. Occult hepatitis B in Mexican patients with HIV, an analysis using nested polymerase chain reaction. Ann Hepatol 2006; 5: 34-40 [PMID: 16531963]
23. Firnhaber C, Viana R, Reyneke A, Schultze D, Malope B, Maskew M, Di Bisceglie A, MacPhail P, Sanne I, Kew M. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis 2009; 13: 488-492 [PMID: 19081280 DOI: 10.1016/j.ijid.2008.08.018]
24. N'Dri-Yoman T, Anglaret X, Messou E, Attia A, Polneau S, Toni T, Chenal H, Seyler C, Gabillard D, Wakasugi N, Eholié S, Danel C. Occult HBV infection in untreated HIV-infected adults in Côte d' Ivoire. Antivir Ther 2010; 15: 1029-1034 [PMID: 21041918 DOI: 10.3851/IMP1641]
25. Opaleye OO, Oluremi AS, Atiba AB, Adewumi MO, Mabayoje OV, Donbraye E, Ojurongbe O, Olowe OA. Occult Hepatitis B Virus Infection among HIV Positive Patients in Nigeria. J Trop Med 2014; 2014: 796121 [PMID: 24868208 DOI: 10.1155/2014/796121]
26. Panigrahi R, Majumder S, Gooptu M, Biswas A, Datta S, Chandra PK, Banerjee A, Chakrabarti S, Bandopadhyay D, De BK, Chakravarty R. Occult HBV infection among anti-HBc positive HIV-infected patients in apex referral centre, Eastern India. Ann Hepatol 2012; 11: 870-875 [PMID: 23109450]
27. Sen S, Panda SP, Shanmuganandan K, Gupta R, Praharaj A. Prevalence of occult hepatitis B amongst Indian human immunodeficiency virus type 1 infected individuals-a pilot study. Med J Armed Forces India 2012; 68: 16-19 [PMID: 24669033 DOI: 10.1016/S0377-1237(11)60127-5]
28. Shire AM, Roberts LR. Occult hepatitis B virus infection: bit player or role player? Hepatology 2011; 54: 760-763 [PMID: 21735471 DOI: 10.1002/hep.24528]
29. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001; 34: 194-203 [PMID: 11431751 DOI: 10.1053/jhep.2001.25172]
30. Gupta S, Singh S. Occult hepatitis B virus infection in ARTnaive HIV-infected patients seen at a tertiary care centre in north India. BMC Infect Dis 2010; 10: 53 [PMID: 20205948 DOI: 10.1186/1471-2334-10-53]
31. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170 [PMID: 17112622 DOI: 10.1016/j.jhep.2006.10.007]
32. Schmeltzer P, Sherman KE. Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci 2010; 55: 3328-3335 [PMID:20927592 DOI: 10.1007/s10620-010-1413-0]
33. Squadrito G, Spinella R and Raimondo G. The clinical significance of occult HBV infection. Ann Gastroenterol 2014; 27: 15-19 [PMID:24714731]
34. Gerlich WH. Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy. Intervirology 2014; 57: 202-211 [PMID:25034489 DOI: 10.1159/000360949]
35. Khamduang W, Ngo-Giang-Huong N, Gaudy-Graffin C, Jourdain G, Suwankornsakul W, Jarupanich T, Chalermpolprapa V, Nanta S, Puarattana-Aroonkorn N, Tonmat S, Lallemant M, Goudeau A, Sirirungsi W. Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women. Clin Infect Dis 2013; 56: 1704-1712 [PMID: 23487379 DOI: 10.1093/cid/cit166]
36. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009-1022 [PMID: 11231956 DOI: 10.1053/gast.2001.22461]
37. Chamorro AJ, Casado JL, Bellido D, Moreno S. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker. Eur J Clin Microbiol Infect Dis 2005; 24: 492-494 [PMID: 15990987]
38. Bloquel B, Jeulin H, Burty C, Letranchant L, Rabaud C, Venard V. Occult hepatitis B infection in patients infected with HIV: report of two cases of hepatitis B reactivation and prevalence in a hospital cohort. J Med Virol 2010; 82: 206-212 [PMID: 20029819 DOI: 10.1002/jmv.21685]
39. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44: S65-S70 [PMID: 16338021 DOI: 10.1016/j.jhep.2005.11.015]
40. Pei R, Grund S, Verheyen J, Esser S, Chen X, Lu M. Spontaneous reactivation of hepatitis B virus replication in an HIV coinfected patient with isolated anti-Hepatitis B core antibodies. Virol J 2014; 11: 9 [PMID: 24444423 DOI: 10.1186/1743-422X-11-9]
41. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174 [PMID:12124405 DOI: 10.1056/NEJMoa013215]
42. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686 [PMID: 16530509 DOI: 10.1053/j.gastro.2005.11.016]
43. Hollinger FB, Dodd RY. Hepatitis B virus traceback and lookback: factors to consider. Transfusion 2009; 49: 176-184 [PMID:19140810 DOI: 10.1111/j.1537-2995.2008.01961.x]
44. Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J, Sun CA, Liaw YF, Chen CJ. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138: 1747-1754 [PMID: 20114048 DOI: 10.1053/j.gastro.2010.01.042]
45. Attia KA, Eholié S, Messou E, Danel C, Polneau S, Chenal H, Toni T, Mbamy M, Seyler C, Wakasugi N, N'dri-Yoman T, Anglaret X. Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients. World J Hepatol 2012; 4: 218-223 [PMID: 22855697 DOI: 10.4254/wjh.v4.i7.218]
46. Azadmanesh K, Mohraz M, Aghakhani A, Edalat R, Jam S, Eslamifar A, Banifazl M, Moradmand-Badie B, Ramezani A. Occult hepatitis B virus infection in HIV-infected patients with isolated hepatitis B core antibody. Intervirology 2008; 51: 270-274 [PMID: 18841029 DOI: 10.1159/000160217]
47. Bagaglio S, Bianchi G, Danise A, Porrino L, Uberti-Foppa C, Lazzarin A, Castagna A, Morsica G. Longitudinal evaluation of occult hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption. Infection 2011; 39: 121-126 [PMID: 21424854 DOI: 10.1007/s15010-011-0093-9]
48. Bell TG, Makondo E, Martinson NA, Kramvis A. Hepatitis B virus infection in human immunodeficiency virus infected southern African adults: occult or overt-that is the question. PLoS One 2012; 7: e45750 [PMID: 23049685 DOI: 10.1371/journal.pone.0045750]
49. Chadwick D, Doyle T, Ellis S, Price D, Abbas I, Valappil M, Geretti AM. Occult hepatitis B virus coinfection in HIV-positive African migrants to the UK: a point prevalence study. HIV Med 2014; 15: 189-192 [PMID: 24118868 DOI: 10.1111/hiv.12093]
50. Coffin CS, Mulrooney-Cousins PM, Osiowy C, van der Meer F, Nishikawa S, Michalak TI, van Marle G, Gill MJ. Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy. J Clin Virol 2014; 60: 347-353 [PMID: 24881491 DOI: 10.1016/j.jcv.2014.04.021]
51. Dapena M, Figueras C, Noguera-Julian A, Fortuny C, de José MI, Mellado MJ, Gavilán C, Falcón-Neyra MD, Navarro ML, de Ory SJ, López C, Mayol L, Méndez M, Ciria LM, Coll MT, García L, Nuñez E, Espiau M, Soler-Palacín P. Implementation of occult hepatitis screening in the Spanish cohort of HIV-infected pediatric patients. Pediatr Infect Dis J 2013; 32: e377-e379 [PMID:23446444 DOI: 10.1097/INF.0b013e31828e9b99]
52. Hakeem L, Thomson G, McCleary E, Bhattacharyya D, Banerjee I. Prevalence and Immunization Status of Hepatitis B Virus in the HIV Cohort in Fife, Scotland. J Clin Med Res 2010; 2: 34-38 [PMID:22457699 DOI: 10.4021/jocmr2009.12.1282]
53. Liang SH, Chen TJ, Lee SS, Tseng FC, Huang CK, Lai CH, Chiou CP, Wang JL, Chung HC, Lin JN, Kuo YC, Lin HH. Risk factors of isolated antibody against core antigen of hepatitis B virus: association with HIV infection and age but not hepatitis C virus infection. J Acquir Immune Defic Syndr 2010; 54: 122-128 [PMID:20386111 DOI: 10.1097/QAI.0b013e3181daafd5]
54. Lo Re V, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, Tebas P, Stern J, Synnestvedt M, Localio AR, Kostman JR, Strom BL. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44: 315-320 [PMID: 17159655 DOI: 10.1097/qai.0b013e31802ea499]
55. Loustaud-Ratti V, Wagner A, Carrier P, Marczuk V, Chemin I, Lunel F, Fouchard-Hubert I, Ahmed SS, Abergel A, Rousseau A, Lefebvre A, Debette-Gratien M, Denis F, Alain S. Distribution of total DNA and cccDNA in serum and PBMCs may reflect the HBV immune status in HBsAg+ and HBsAg-patients coinfected or not with HIV or HCV. Clin Res Hepatol Gastroenterol 2013; 37: 373-383 [PMID: 23477988 DOI: 10.1016/j.clinre.2012.11.002]
56. Morsica G, Ancarani F, Bagaglio S, Maracci M, Cicconi P, Cozzi Lepri A, Antonucci G, Bruno R, Santantonio T, Tacconi L, Baldelli F, Piscopo R, Santoro D, Lazzarin A, D'Arminio Monforte A. Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features. Infection 2009; 37: 445-449 [PMID:19669092 DOI: 10.1007/s15010-008-8194-9]
57. Mphahlele MJ, Burnett RJ, Kyaw T, Schoeman HS, Aspinall S. Immunogenicity and safety of yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB) in South African children. S Afr Med J 2004; 94: 280-281 [PMID: 15150941]
58. Neau D, Winnock M, Jouvencel AC, Faure M, Castéra L, Legrand E, Lacoste D, Ragnaud JM, Dupon M, Fleury H, Lafon ME, Dabis F. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis 2005; 40: 750-753 [PMID: 15714424 DOI: 10.1086/427882]
59. Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, Johnson M, Gilson R, Tedder R, Geretti AM. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol 2007; 79: 1464-1471 [PMID: 17705185 DOI: 10.1002/jmv.20954]
60. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 36: 869-875 [PMID: 15213572 DOI: 10.1097/00126334-200407010-00015]
61. Shire NJ, Rouster SD, Stanford SD, Blackard JT, Martin CM, Fichtenbaum CJ, Sherman KE. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44: 309-314 [PMID:17159656 DOI: 10.1097/QAI.0b013e31802e29a9]
62. Tramuto F, Maida CM, Colomba GM, Di Carlo P, Vitale F. Prevalence of occult hepatitis B virus infection in a cohort of HIVpositive patients resident in Sicily, Italy. Biomed Res Int 2013; 2013:859583 [PMID: 24063015 DOI: 10.1155/2013/859583]
63. Tsui JI, French AL, Seaberg EC, Augenbraun M, Nowicki M, Peters M, Tien PC. Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women. Clin Infect Dis 2007; 45: 736-740 [PMID: 17712758 DOI: 10.1086/520989]